Early Cardiac Involvement in Treatment-Na&#xef;ve, Autoantibody-Seropositive Patients with Autoimmune Rheumatic Diseases in the Prodromal Phase-A Cardiovascular Magnetic Resonance Study

Lung Cancer

Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial

Lung Cancer

Barlesi F, Ahn JS, Solomon BJ, Nishio M, Dziadziuszko R, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, Hochmair M, de Marinis F, Migliorino MR, Bondarenko I, Xu T, Bara I, Ding B, Ngiam C, Petric P, Wu YL

doi: 10.1016/j.lungcan.2026.109385

Lung Cancer

Double-dose firmonertinib as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer harboring EGFR L858R mutation: a prospective, multicenter, phase II study (FIRM)

Nat Commun

Shen B, Wang C, Zhang L, Zhu Y, Zhang X, Wang X, Guo Z, Wang L, Wang X, Zhu L, Zhou Y, Liao D, Shi M

doi: 10.1038/s41467-026-68554-6

COMMENTED

Asthma

Three Biologic-Naïve Patients with Allergic Bronchopulmonary Aspergillosis Showing Significant Clinical Improvement with Tezepelumab

★ 1 Recommended by Dr. med. Martin Frey, Faculty Member

★ 3 Recommended and commented by Dr Marcus Hesse, Faculty Member

J Asthma Allergy

Yamaguchi M, Yamazaki A, Nakagawa H, Kinose D, Nakano Y

doi: 10.2147/JAA.S541770

Asthma

Dupilumab-induced eosinophilia in severe asthma: 2-year follow-up real-life evidence from biologic-naïve and previously treated patients

Respir Med

Bellver-Asperilla C, Romero Ortíz A, Cabrerizo-Carreño H, Orozco Echeverría S, González Compta X, Fors MG, Andujar Ruiz A, Suárez-Cuartín G, Zamora NP, Ardanuy C, Pérez SS, Muñoz-Esquerre M

doi: 10.1016/j.rmed.2026.108855

RECOMMENDED

ARDS

Different Duration of Prone Positioning Treatment for Patients with Acute Respiratory Distress Syndrome in Intensive Care Unit Patients: A Prospective Randomized Clinical Study

★ 1 Recommended by Dr. med. Martin Frey, Faculty Member

J Clin Med

Hsu CW, Liu SM, Yang CY, Sun SF, Kuo SH, Chu KA

doi: 10.3390/jcm14207261

Lung Cancer

Retifanlimab versus placebo in combination with platinum-based chemotherapy in patients with first-line non-squamous or squamous metastatic non-small-cell lung cancer (POD1UM-304): a phase 3, multiregional, placebo-controlled, double-blind, randomised study

Lancet Respir Med

Lu S, Vynnychenko O, Kulyaba Y, Kuchava V, Ibrahim A, Moiseenko F, Arslan C, Nguyen DT, Petrovic M, Cicin I, Bibichadze K, Cil T, Shi J, Olmez OF, Gogishvili M, Artac M, Nguyen HG, Cornfeld M, Tian C, Munteanu MC, Sette CVM, Bondarenko I, POD1UM-304 Study Team

doi: 10.1016/S2213-2600(25)00209-7

Further Publications

Patient Factors and Clinical Efficacy of Early Identification and Treatment of COPD and Asthma

Am J Respir Crit Care Med

Tardif A, Whitmore GA, Vandemheen KL, Bergeron C, Boulet LP, Côté A, McIvor RA, Penz E, Field SK, Lemière C, Mayers I, Bhutani M, Azher T, Lougheed MD, Gupta S, Ezer N, Licskai CJ, Hernandez P, Ainslie M, Alvarez GG, Mulpuru S, Aaron SD

doi: 10.1164/rccm.202505-1260OC

RECOMMENDED

Lung Cancer

Autoantibody spark response predicts treatment outcome in patients receiving chemoradiation followed by durvalumab therapy

★ 1 Recommended by Dr. med. Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Sci Rep

Mori T, Kitagawa M, Hasegawa T, Someya M, Tsuchiya T, Gocho T, Honjo T, Date M, Morii M, Miyamoto A, Futami J

doi: 10.1038/s41598-025-12069-5

RECOMMENDED

Lung Cancer

The Italian Mauris Phase IIIb Trial of Atezolizumab Plus Carboplatin and Etoposide for Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer: 3-Year End-of-Study Results

★ 1 Recommended by Dr. med. Martin Frey, Faculty Member

Clin Lung Cancer

Morgillo F, Del Signore E, Bria E, de Marinis F, Ciardiello F, Garassino MC, Stefani A, Verderame F, Morabito A, Sbrana A, Tonini G, Gilli M, Berardi R, Taveggia PA, Bearz A, Delmonte A, Migliorino MR, Gridelli C, Fadda GM, Iero M, Ardizzoni A

doi: 10.1016/j.cllc.2025.07.003

Pneumology

Early Cardiac Involvement in Treatment-Naïve, Autoantibody-Seropositive Patients with Autoimmune Rheumatic Diseases in the Prodromal Phase-A Cardiovascular Magnetic Resonance Study

Related content

Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial

Double-dose firmonertinib as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer harboring EGFR L858R mutation: a prospective, multicenter, phase II study (FIRM)

Three Biologic-Naïve Patients with Allergic Bronchopulmonary Aspergillosis Showing Significant Clinical Improvement with Tezepelumab

Dupilumab-induced eosinophilia in severe asthma: 2-year follow-up real-life evidence from biologic-naïve and previously treated patients

Different Duration of Prone Positioning Treatment for Patients with Acute Respiratory Distress Syndrome in Intensive Care Unit Patients: A Prospective Randomized Clinical Study

Retifanlimab versus placebo in combination with platinum-based chemotherapy in patients with first-line non-squamous or squamous metastatic non-small-cell lung cancer (POD1UM-304): a phase 3, multiregional, placebo-controlled, double-blind, randomised study

Patient Factors and Clinical Efficacy of Early Identification and Treatment of COPD and Asthma

Autoantibody spark response predicts treatment outcome in patients receiving chemoradiation followed by durvalumab therapy

The Italian Mauris Phase IIIb Trial of Atezolizumab Plus Carboplatin and Etoposide for Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer: 3-Year End-of-Study Results